The Evolution Of Drug Regulation In Post-Brexit Britain

Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.

UK Drugs — The UK's ILAP aims to marry regulatory and HTA processes to deliver quicker market access for drugs • Source: Shutterstock

The post-Brexit UK is continuing to make its way outside the EU with a view to ensuring it is an important market for attracting investment, launching innovative new medicines and conducting clinical research. The Pink Sheet takes a look at how the country is managing to develop its regulatory and market access environment in an effort to achieve those aims.

In 2022, the importance of international collaborations and regulatory reliance was cemented as a way of securing quicker marketing authorizations....